Literature DB >> 3973022

Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. Dose-response relationships and comparison to nitroprusside.

B E Jaski, M A Fifer, R F Wright, E Braunwald, W S Colucci.   

Abstract

Milrinone is a potent positive inotropic and vascular smooth muscle-relaxing agent in vitro, and therefore, it is not known to what extent each of these actions contributes to the drug's hemodynamic effects in patients with heart failure. In 11 patients with New York Heart Association class III or IV congestive heart failure, incremental intravenous doses of milrinone were administered to determine the dose-response relationships for heart rate, systemic vascular resistance, and inotropic state, the latter measured by peak positive left ventricular derivative of pressure with respect to time (dP/dt). To clarify further the role of a positive inotropic action, the relative effects of milrinone and nitroprusside on left ventricular stroke work and dP/dt were compared in each patient at doses matched to cause equivalent reductions in mean arterial pressure or systemic vascular resistance, indices of left ventricular afterload. Milrinone caused heart rate, stroke volume, and dP/dt to increase, and systemic vascular resistance to decrease in a concentration-related manner. At the two lowest milrinone doses resulting in serum concentrations of 63 +/- 4 and 156 +/- 5 ng/ml, respectively, milrinone caused significant increases in stroke volume and dP/dt, but no changes in systemic vascular resistance or heart rate. At the maximum milrinone dose administered (mean serum concentration, 427 +/- 11 ng/ml), heart rate increased from 92 +/- 4 to 99 +/- 4 bpm (P less than 0.01), mean aortic pressure fell from 82 +/- 3 to 71 +/- 3 mmHg (P less than 0.01), right atrial pressure fell from 15 +/- 2 to 7 +/- 1 mmHg (P less than 0.005), left ventricular end-diastolic pressure fell from 26 +/- 3 to 18 +/- 3 (P less than 0.005), stroke volume index increased from 20 +/- 2 to 30 +/- 2 ml/m2 (P less than 0.005), stroke work index increased from 14 +/- 2 to 21 +/- 2 g X m/m2 (P less than 0.01), and dP/dt increased from 858 +/- 54 to 1,130 +/- 108 mmHg/s (P less than 0.005). When compared with nitroprusside for a matched reduction in mean aortic pressure or systemic vascular resistance, milrinone caused a significantly greater increase in stroke work index at the same or lower left ventricular end-diastolic pressure. Milrinone caused a concentration-related increase in dP/dt (32% increase at maximum milrinone dose), whereas nitroprusside had no effect. These data in patients with severe heart failure indicate that in addition to a vasodilating effect, milrinone exerts a concentration-related positive inotropic action that contributes significantly to the drug's overall hemodynamic effects. The positive inotropic action occurs at drug levels that do not exert significant chronotropic or vasodilator effects.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3973022      PMCID: PMC423546          DOI: 10.1172/JCI111742

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  21 in total

1.  Hemodynamic determinants of the maximal rate of rise of left ventricular pressure.

Authors:  A G WALLACE; N S SKINNER; J H MITCHELL
Journal:  Am J Physiol       Date:  1963-07

2.  Studies on the first derivative of the ventricular pressure pulse in man.

Authors:  W L GLEASON; E BRAUNWALD
Journal:  J Clin Invest       Date:  1962-01       Impact factor: 14.808

3.  Ventricular function. I. Starling's law of the heart studied by means of simultaneous right and left ventricular function curves in the dog.

Authors:  S J SARNOFF; E BERGLUND
Journal:  Circulation       Date:  1954-05       Impact factor: 29.690

4.  Comparative hemodynamic effects of inotropic and vasodilator drugs in severe heart failure.

Authors:  E Mikulic; J N Cohn; J A Franciosa
Journal:  Circulation       Date:  1977-10       Impact factor: 29.690

5.  Intropic effect of tachycardia and poststimulation potentiation in the conscious dog.

Authors:  F Mahler; C Yoran; J Ross
Journal:  Am J Physiol       Date:  1974-09

6.  Comparative responses to dobutamine and nitroprusside in patients with chronic low output cardiac failure.

Authors:  C Berkowitz; L McKeever; R P Croke; W R Jacobs; H S Loeb; R M Gunnar
Journal:  Circulation       Date:  1977-12       Impact factor: 29.690

7.  Effects of changes in preload, afterload and inotropic state on ejection and isovolumic phase measures of contractility in the conscious dog.

Authors:  F Mahler; J Ross; R A O'Rourke; J W Covell
Journal:  Am J Cardiol       Date:  1975-05       Impact factor: 2.778

8.  Influence of acute changes in preload, afterload, contractile state and heart rate on ejection and isovolumic indices of myocardial contractility in man.

Authors:  M A Quinones; W H Gaasch; J K Alexander
Journal:  Circulation       Date:  1976-02       Impact factor: 29.690

9.  Characterization of the cardiotonic effects of milrinone, a new and potent cardiac bipyridine, on isolated tissues from several animal species.

Authors:  A A Alousi; G P Stankus; J C Stuart; L H Walton
Journal:  J Cardiovasc Pharmacol       Date:  1983 Sep-Oct       Impact factor: 3.105

10.  Cardiotonic activity of milrinone, a new and potent cardiac bipyridine, on the normal and failing heart of experimental animals.

Authors:  A A Alousi; J M Canter; M J Montenaro; D J Fort; R A Ferrari
Journal:  J Cardiovasc Pharmacol       Date:  1983 Sep-Oct       Impact factor: 3.105

View more
  36 in total

1.  Basal Spontaneous Firing of Rabbit Sinoatrial Node Cells Is Regulated by Dual Activation of PDEs (Phosphodiesterases) 3 and 4.

Authors:  Tatiana M Vinogradova; Syevda Sirenko; Yevgeniya O Lukyanenko; Dongmei Yang; Kirill V Tarasov; Alexey E Lyashkov; Nevin J Varghese; Yue Li; Khalid Chakir; Bruce Ziman; Edward G Lakatta
Journal:  Circ Arrhythm Electrophysiol       Date:  2018-06

Review 2.  Adverse effects associated with the newer inotropic agents.

Authors:  M W Webster; D N Sharpe
Journal:  Med Toxicol       Date:  1986 Sep-Oct

Review 3.  PDE3 Inhibitors Repurposed as Treatments for Age-Related Cognitive Impairment.

Authors:  Shuichi Yanai; Shogo Endo
Journal:  Mol Neurobiol       Date:  2018-10-11       Impact factor: 5.590

Review 4.  Studies on the mechanism of action of the bipyridine milrinone on the heart.

Authors:  A E Farah; C J Frangakis
Journal:  Basic Res Cardiol       Date:  1989       Impact factor: 17.165

5.  Additive positive inotropic effects of milrinone, ouabain and calcium in diseased human ventricular myocardium.

Authors:  L Brown; M Näbauer; E Erdmann
Journal:  Klin Wochenschr       Date:  1986-08-01

Review 6.  Therapeutic potential of PDE modulation in treating heart disease.

Authors:  Walter Knight; Chen Yan
Journal:  Future Med Chem       Date:  2013-09       Impact factor: 3.808

7.  Acute hemodynamic effects and preload-dependent cardiovascular profile of the partial phosphodiesterase inhibitor nanterinone in patients with mild to moderate heart failure.

Authors:  W J Remme; M van der Ent; G L Bartels; D van Schelven; D C van Hoogenhuyze; X H Krauss; H A Kruijssen; C J Storm
Journal:  Cardiovasc Drugs Ther       Date:  1996-05       Impact factor: 3.727

Review 8.  Phosphodiesterase inhibition in heart failure.

Authors:  Matthew Movsesian; Josef Stehlik; Fabrice Vandeput; Michael R Bristow
Journal:  Heart Fail Rev       Date:  2008-12-19       Impact factor: 4.214

Review 9.  Current status of phosphodiesterase inhibitors in the treatment of congestive heart failure.

Authors:  T A Fischer; R Erbel; N Treese
Journal:  Drugs       Date:  1992-12       Impact factor: 9.546

10.  The effect of milrinone infusion on right ventricular function during coronary anastomosis and early outcomes in patients undergoing off-pump coronary artery bypass surgery.

Authors:  Hyong Rae Jo; Woo Kyung Lee; Yong Ho Kim; Jin Hye Min; Young Keun Chae; In Gyu Choi; Young Sin Kim; Yong Kyung Lee
Journal:  Korean J Anesthesiol       Date:  2010-08-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.